| Identification | Back Directory | [Name]
cRIPGBM | [CAS]
2361988-77-2 | [Synonyms]
cRIPGBM(chloride)
1-Benzyl-3-(4-fluorobenzyl)-2-methyl-4,9-dioxo-4,9- dihydro-1H-naphtho[2,3-d]imidazol-3-ium chloride | [Molecular Formula]
C26H20ClFN2O2 | [MDL Number]
MFCD34596421 | [MOL File]
2361988-77-2.mol | [Molecular Weight]
446.91 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [color ]
Light yellow to yellow | [InChI]
1S/C26H20FN2O2.ClH/c1-17-28(15-18-7-3-2-4-8-18)23-24(29(17)16-19-11-13-20(27)14-12-19)26(31)22-10-6-5-9-21(22)25(23)30;/h2-14H,15-16H2,1H3;1H/q+1;/p-1 | [InChIKey]
IHNGETPFBJHWFE-UHFFFAOYSA-M | [SMILES]
O=C1C2=C([N+](CC3=CC=C(F)C=C3)=C(C)N2CC4=CC=CC=C4)C(C5=C1C=CC=C5)=O.[Cl-] |
| Hazard Information | Back Directory | [Uses]
cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models[1]. | [Biological Activity]
cRIPGBM is an apoptosis inducer (GBM-1/-5/-39 EC50 = 63/95/290 nM; human neural progenitor cells (NPCs)/astrocytes/lung fibroblasts EC50 = 190/710/960 nM) th at binds receptor-interacting protein kinase 2 (RIPK2RIP2) and promotes the formation of a proapoptotic RIPK2/caspase-1 complex. Cell type-selective metabolic redox conversion of RIPGBM to cRIPGBM in glioblastoma multiforme (GBM) cancer stem cells (CSCs) form the basis of selective GBM CSCs apoptosis induction by RIPGBM over non-GBM cultures. | [in vivo]
cRIPGBM chloride (50 mg/kg; p.o.; twice daily for 5 weeks) inhibits tumor growth in patient-derived GBM CSC intracranial xenograft mouse models[1].
| Animal Model: | Orthotopic intracranial xenograft model in mouse[1] | | Dosage: | 50 mg/kg | | Administration: | PO; twice daily, 8 h apart, starting at day 7 postinjection; last for 5 weeks | | Result: | Monitored by Fluorescence Tomography System. Decreased the tumor signal, as well as tumor size. |
| [IC 50]
Caspase-1; RIPK2 | [References]
[1] Lucki NC, et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. DOI:10.1073/pnas.1816626116 |
|
| Company Name: |
commedx
|
| Tel: |
010-46598925 18519000250 |
| Website: |
http://www.commedx.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|